SCHEMBL30730587

SCHEMBL30730587

O=C(Cc1cnccn1)N1CCC(n2nnc(-c3ccc(F)cc3)n2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.43
LMNA P02545 2/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
RORC P51449 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
NAMPT P43490 2/20 0.39
AOC3 Q16853 2/20 0.39
CNR1 P21554 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.37
PRCP P42785 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
CALCRL Q16602 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730597 0.78 MAPK1 (0.44) MAPK1LMNAALOX15TSHRDRD2
SCHEMBL30730594 0.77 MAPK1 (0.45) MAPK1LMNAALOX15TSHRDRD2
SCHEMBL30730585 0.77 LMNA (0.47) MAPK1LMNAALOX15TSHRDRD2
SCHEMBL30730575 0.76 LMNA (0.50) MAPK1LMNAALOX15TSHRCNR1
SCHEMBL30730573 0.76 MAPK1 (0.46) MAPK1LMNAALOX15TSHRDRD2
SCHEMBL30730624 0.72 MEN1 (0.48) MEN1KMT2A
SCHEMBL20002747 0.71 MAPT (0.44) RORCNAMPTMAPTRAB9AALDH1A1
SCHEMBL30730663 0.69 PKM (0.44) MAPK1LMNAALOX15TSHRDRD2
SCHEMBL30730500 0.69 DRD2 (0.41) LMNATSHRDRD2DRD4DRD3
SCHEMBL30730669 0.69 LMNA (0.41) LMNADRD2DRD4DRD3AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 MAPK1 1861/4885LMNA 1838/4885ALOX15 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.